31 August 2020 Blog Post: California’s New Blueprint to Safe Opening

31 August 2020 Blog Post: California's New Blueprint to Safe Opening

On Friday, Governor Newsom outlined a new blueprint for reopening California – county by county. Replacing the watch list is now a color scheme based on two metrics: case rate, and positivity rate (percent of positive tests). The color determines how businesses can operate within that county.
 
The governor described the new framework as “simple, stringent and slow.” But let’s delve into it a little further
 
State director of Health and Human Services Dr. Mark Ghaly said case rates and positivity rates are the best, earliest numbers on which to base reopening decisions. The first metric is new daily cases per 100,000 population – those who have been following posts here will recognize this rate. The threshold rate to move from purple to red is to drop below 7. Los Angeles County is currently at 10.49 (Figure 1 below), although there is likely at least a week of lag to this value.
 
So where do these color levels actually come from? They appear to be loosely based upon the Global Health Institute at Harvard’s key metrics for COVID suppression. Working backwards, they note that at a level greater than 25, a municipality has passed into uncontrolled spread and “will require the use of stay-at-home orders and/or advisories to mitigate the disease.” Los Angeles County levels exceeded 25 for the entire month of July (Figure below).
At case rate levels between 10 and 25, community spread is accelerating at dangerous levels, most typically on its way upwards. Of interest, most counties will plateau at a rate between 1 and 10 but the Harvard group really only considers a region to be ‘on track’ at a rate under 1 – calling this the ‘green’ level.. “At the green level, jurisdictions are on track for containment so long as they maintain maintenance levels of viral testing and contact tracing, sufficient to control spikes and outbreaks. It is not enough to get to green; one also has to plan to stay green.” Los Angeles’ rate was last below 1 the week of March 13th (Figure above).
 
Test positivity rate seems to have been taken from World Health Organization guidelines which recommends a positive test rate of less than 10% for viral containment. However, the countries most successful in containing COVID have rates of 3% or less. There is an important caveat to this recommendation made by the WHO – which is that “percentage positive samples can be interpreted only with comprehensive surveillance and testing of suspected cases.” The percent positive is, in fact, a critical measure because it gives us an indication how widespread infection is in the area where the testing is occurring—and whether levels of testing are keeping up with levels of disease transmission. To Governor Newsom’s credit, he has expanded testing to double its current capacity. There are two ways to decrease test positivity: 1. Fewer infections or 2. More testing. Either serve the same end.
 
Lastly, I do very much concur with the “slow” aspect of reopening. In this revamped plan, instead of 14 days with measurements below the mandated levels to move from one tier to another, it will now take 21 days. Further, while the state will require 21 days in order to lift restrictions, it will only take 14 days of too-high numbers to move to a more restrictive state. This shows that Dr. Ghaly and the State Health Department have learned something from the debacle that was the July surge. Counties like Los Angeles went blindly ahead with successive reopening steps without realizing or accounting for the mounting delays in test result returns. Therefore, once it became clear that COVID-19 was surging, it was too late to put on the brakes. 21 days should provide enough time to thoughtfully examine case data – given that case reporting lags during July in our clinic were 11-12 days at one point.
 
I do have two critiques of what is otherwise a very reasonable and thoughtful plan. Traditionally, infectious diseases are tracked through an SEIR model where individuals are categorized as: susceptible [S], exposed [E], infected [I], and recovered [R]. Thus far, the State of California has made no attempt to quantify those that remain susceptible. Such would require an extensive, population-based serosurvey – something that has been done in New York State. If I were pressed for an answer, I would estimate that 85-90% of the California population remains susceptible with significant geographic variance.
 
The second critique relates to contact tracing – which is the manner in which we identify those exposed [E] in the SEIR model. In Los Angeles County, contact tracing has been abysmal. Only 63.6% of overall contacts have completed their interview since the start of the pandemic and that number slips 60.8% of those exposures occurring within the last week. The current recommendation is that at least 90% of contacts for each new case must be traced within 48 hours in order to contain COVID. With such a low percentage of contacts successfully traced, it is unlikely that the state will be able to successfully identify and isolate sources of disease spread fast enough to prevent new outbreaks.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

29 August 2020 Blog Post: The Flu Shot, Myths and Mysteries in the 2020/2021 season

29 August 2020 Blog Post: The Flu Shot, Myths and Mysteries in the 2020/2021 season

I have been receiving a lot of questions lately about the 2020/2021 seasonal flu shot. This is because the call has gone out to the public that having a flu shot is one of the steps that can be taken to combat COVID-19.
 
“Everyone above the age of 6 months should be getting the flu vaccine,” said Dr. Uchenna Ikediobi, an assistant professor of general internal medicine and infectious diseases at Yale University. According to the The New York Times: “Growing concern over the combined impact of the two viruses [flu and COVID-19] has even led some to mandate the vaccine. The University of California system announced this month that it would require all its employees and students to get a flu shot by Nov. 1. And Massachusetts is requiring all students between 6 months and 30 years old to get the flu shot by the end of the year.”
 
Personally, I’m not a proponent of mandating vaccination unless you are in the military and face the potential of biologic warfare. Moreover, it seems that mandates cause an unintended backlash insofar that those with strong feelings about being told what to do (but who may otherwise be ambivalent about vaccination itself) find themselves in a position of refusing to be vaccinated.
 
Additionally, flu vaccine efficacy hasn’t been all that great in recent years (Figure 1) below. In fact, for the 2017/2018 season it was less that 20% effective for all age groups. Of course, we will not know the effectiveness of the 2020/2021 vaccine until the season has ended. Nevertheless, mandating a vaccine with 90-95% effectiveness seems like an easier task than mandating one with at 20-40%.
 
Each year, we take early cues of flu season severity from Australia. Unsurprisingly, with COVID-19 mitigation efforts in full swing, the Australia Department of Health reports “Following a high start to the 2020 interseasonal period, currently, influenza and influenza-like illness (ILI) activity are lower than average across all systems for this time of year. At the national level, notifications of laboratory-confirmed influenza have substantially decreased since mid-March and remain low.” They conclude, ” it is likely that there is minimal impact on society due to influenza circulation in the 2020 season.” There have been 36 deaths attributed to influenza in Australia this season.
 
As noted above, US public health officials are concerned about the potential dual effect of Covid-19 and influenza (so called “twindemic”) that will further overburden hospitals and testing locations. For me, being able to distinguish between COVID-19 and influenza became of primary concern – given the significant overlap of symptoms and that we have effective treatment for influenza. To this end, we have point-of-care testing both for COVID-19 and influenza available in the office.
 
Timing of the flu shot is important as well. Many retailers such as retail pharmacies already have flu shots in stock and are advertising its availability. Here at Santa Monica Primary Care, we don’t purchase in quite such large volumes so receive our flu shots a bit later in the year – but expect to have them in stock in the next week or so.
 
Buried in the CDC guidelines (now I’ve bashed the CDC response to COVID-19 but they have a good track record when it comes to influenza) is a short statement on timing. “Make plans to get vaccinated early in fall, before flu season begins. CDC recommends that people get a flu vaccine by the end of October. However, getting vaccinated early (for example, in July or August) is likely to be associated with reduced protection against flu infection later in the flu season, particularly among older adults.”
 
Each year, Columbia University School of Public Health runs a predictive model of influenza by major US metropolitan area. I have been using this resource in clinical planning for the last several years and have found it to be spot on. This year, in Los Angeles, they predict flu cases to peak the week of December 22nd (https://cpid.iri.columbia.edu/). Cases are at a very low level in September and October and begin to risk in mid-November. I would expect a much lower volume of flu cases given significant decrease in travel, closed schools as well as widespread COVID-19 mitigation efforts.
 
Additional CDC fine print pertains to the “high dose” Fluzone Quadrivalent flu vaccine approved for people 65 years and older. While there are studies suggesting that this formulation may reduce flu-related hospitalization, “The CDC and its Advisory Committee on Immunization Practices have not expressed a preference for any flu vaccine indicated for people 65 years and older.” Some adverse events were reported more frequently after vaccination with trivalent Fluzone High-Dose than after standard-dose inactivated flu vaccines. But most people had minimal or no adverse events after receiving the Fluzone High-Dose vaccine. We do not stock the high-dose vaccine in our clinic, but retail pharmacies do routinely carry this formulation.
 
So, to sum up, what do I recommend?
1. Get a flu shot – whether it is mandated or not. Hopefully it works more like 2016/2017 than 2017/2018.
2. Have your kids get a flu shot – the vaccine has worked better in ages 2-17 in every year.
3. Get one before October – but remember the month of September tends to go by very quickly.
4. If you are over 65 – get a flu shot. Either the Fluzone Quadrivalent or the standard-dose.
5. Buckle up for peak flu season in Los Angeles to be in late December / early January.
6. If you have fever, chills, or any symptoms that could be flu or COVID-19, call our office – we can distinguish between the two.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

28 August 2020 Blog Post: COVID-19 Update Abbott Laboratories $5 Rapid Antigen Test and Your Government

28 August 2020 Blog Post: COVID-19 Update Abbott Laboratories $5 Rapid Antigen Test and Your Government

President Trump will announce tonight at the RNC that the US Government will acquire 150 million of Abbott Laboratories rapid antigen test for $750 million ($5/test). These are intended to be “deployed” to nursing homes, schools and other areas with populations at high risk.
 
Abbott Laboratories has estimated that they will be able to produce 50 million of these tests monthly beginning in October. President Trump has previously stated that he would prefer less COVID-19 testing not more.
 
The US Government will be the sole purchaser of this reasonably priced, easily administered rapid test for the months of October, November and December. Preliminary data suggests that the test is quite accurate, with very robust sensitivity and specificity. Rather than being distributed to public health departments and healthcare providers, it will be up to your government as to who has access.
 
We previously encountered a lack of availability with Abbott’s IDNow platform – famously displayed by President Trump at a White House press conference. This too was allocated to ‘high risk’ areas identified by the Federal Government. Our clinic still is on a waiting list where we have been since March.
 
So the allocation of this exciting and reasonably priced testing technology will be in hands on an administration who just this week, convinced the CDC to advocate for testing only those individuals with symptoms – despite a well documented presymptomatic (but still infectious) phase of COVID-19. For the general public, perhaps some tests will become available in early 2021.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

27 August 2020 Blog Post: COVID-19 Update in Los Angeles County

27 August 2020 Blog Post: COVID-19 Update in Los Angeles County

Headlines such as the one in the linked article below (“Coronavirus trends falling in LA County; health officer says he knows why”) make me very nervous. I think there are a couple of reasons behind my trepidation. First off, I think cautious optimism should be expressed exactly as such. Secondly, the Los Angeles County Health Department doesn’t have the best COVID-19 track records. They mistakenly opened up in person activities such as gyms in mid-June when case rates plateaued but had not dropped. That (and the July 4th weekend) led to the sharp increase in cases through July.
 
Dr. Davis states – “Cautious reopening means we take to heart the lessons we learned from July and move forward in a new normal of making the infection-control practices part of our day-to-day lives for the foreseeable future.”
 
Here’s the problem I am having with Dr. Davis’ approach – I don’t at all feel comfortable with the shape of Los Angeles County’s epidemic curve (Figure 1 below). Typically an epidemic curve will follow an S-shaped distribution. Remember months ago when ‘flattenning the curve’ was drummed into our collective consciousness? Well the LA County case curve is no longer flat – it has been decimated. From the 7/17 case peak until now, 5 weeks later, we have dropped back to pre-July surge rates. This is not the usual pattern for an epidemic curve. 
We see a similar trend with mortality rates as well (Figure 2). The drop from 8/7 until 8/21 is really astonishing with almost a 50% decrease in deaths due to COVID-19. But look at the pattern from the May peak of 0.44 deaths per day per 100,000 population – mortality rates slowly trended down over a 6 week period. Now we have learned quite a bit since that time in how to care for severe COVID-19 cases so perhaps this steep drop in mortality is due to better care. Certainly that is one plausible explanation.
But the last curve (Figure 3) is the one that concerns me the most – testing rates. These are down 33% from their mid-July peak. To me it is not surprising that we are seeing fewer cases in the context of less testing. I would be far more convinced of a true decrease in COVID-19 in the County had testing not dropped off so dramatically.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

24 August 2020 Blog Post: COVID-19 Update Absolute versus Relative Risk

24 August 2020 Blog Post: COVID-19 Update Absolute versus Relative Risk

The Trump Administration today has taken up the call of the convalescent serum “breakthrough” by spreading the notion that this treatment would save 30-50 individuals out of 100 infected with COVID-19. This is false and those saying such have made a fundamental error in mistaking absolute risk for relative risk. Relative risk is a basic Epidemiologic concept covered in any first year, introductory class.
 
Some examples of the false soundbites:
 
1. Michael Caputo (Health and Human Services Assistant Director – no medical training): “If you’re one of the 35 people out of a hundred who survive severe COVID symptoms because of convalescent plasma, you’re damn right this is a BREAKTHROUGH.”
2. Alyssa Farah (White House Director of Communications – BA in Journalism and Public Policy, no medical training): “Mayo Clinic shows Convalescent Plasma will reduce mortality from COVID by as much as 30 to 50%. These are REAL American lives that will be saved as a result of this EUA.”
 
The Mayo Clinic study reported that convalescent serum reduced the 7-day death rate from 11.9% to 8.7%, not that it would “stop” 35 out of 100 deaths. In reality, 3 more people out of 100 may survive when treated, not 35. Or, to put more bluntly, 97 of 100 would still be expected to die.
 
Convalescent serum is not a miracle. Treatment of severe COVID-19 manifestations are best treated with prone positioning, oxygen support, dexamethasone, antithrombotics to prevent clots, and remdesivir (an antiviral originally developed for Ebola). Convalescent serum still has a role in compassionate use scenarios – but 97 out of 100 patients relying on its efficacy alone will still die.
 
Those are facts.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

23 August 2020 Blog Post: COVID-19 Update On Convalescent Plasma and Today’s “Big Announcement”

23 August 2020 Blog Post: COVID-19 Update On Convalescent Plasma and Today’s “Big Announcement”

My presumption that today’s “major therapeutic breakthrough” announcement with President Trump and Secretary Azar will be about blood plasma as a #COVID19 treatment. It is a refrain that is still echoing from our Hydroxychloroquine experience and one, apparently, that this Administration is willing to sing again. Like Hydroxychloroquine in March, convalescent plasma has promise but has not been rigorously studied and, therefore, is not ready for this (literal) primetime announcement.
 
But, backing up, I was a bit surprised this week when the U.S. Food and Drug Administration halted its imminent Emergency Use Authorization of convalescent plasma in the treatment of hospitalized COVID-19 patients. This decision occurred after infectious disease experts, including Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), H. Clifford Lane, Clinical Director of NIAID, and Francis S. Collins, MD, director of the National Institutes of Health, warned the agency that data on its efficacy were lacking.
 
The use of convalescent plasma dates back to the 1890’s when antibodies were first used to protect against bacterial toxins before the introduction of antibiotics. Modern formulations of intravenous immunoglobulin (IVIG), pooled from thousands of healthy donors, is still used today to prevent viral infections in certain patient populations. As a physician treating COVID-19 patients, I have been reasonably enthusiastic about the potential of convalescent serum in the treatment of severe cases. In fact, I have encouraged patients of mine that have recovered clinically from COVID-19 and have negative follow-up testing to reach out to the Red Cross and donate to this effort.
 
To date in the US, more than 66,000 individuals have received convalescent plasma, most under a “compassionate use” basis for those with severe illness. The difficulty in this effort is that no control groups have been run – in other words, those receiving convalescent plasma were not matched with another of similar age, gender and underlying conditions who did not receive this treatment. But, unlike Hydroxychloroquine, it does appear that this treatment is generally safe (Reference: Joyner, M. J. et al. J. Clin. Invest. https://doi.org/10.1172/JCI140200 (2020).)
 
Given that large, randomized, placebo controlled clinical trials do not exist, we are left trying to piece together evidence from smaller tests. One recent study combined data from more than 800 participants across a dozen studies – the treatment decreasedCOVID-19 mortality from 26% to 13% among those with severe illness (Reference: Joyner, M. J. et al. Preprint at medRxiv. https://doi.org/10.1101/2020.07.29.20162917 (2020).
 
So what we are left with is a fuzzy picture just now starting to come into focus. So (going out on a limb), today’s announcement of a “major breakthrough” is unsupported. Further, convalescent serum only functions as a placeholder until a more specific treatment modality (antiviral for example) or vaccine is developed.
 
So we will wait for additional data – and once again the United Kingdom’s National Health Service may ride to the Epidemiologic rescue. The large RECOVERY trial, which is testing several therapies, including convalescent plasma, in people hospitalized with COVID-19. But the first surge of the pandemic in the UK has largely passed, so researchers do not expect to have results until later in 2020.
 
“There is good science behind convalescent plasma and a good reason for thinking that it may turn out to be an effective treatment,” Dr. Martin Landray, a UK Epidemiologist, has said. “But the bottom line is that we don’t have enough data to know.”

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

19 August 2020 Blog Post: COVID -19 Update

19 August 2020 Blog Post: COVID -19 Update

Do you remember way back in April (ages ago)? Casting your mind to the distant recesses of COVD-19, you may remember a Columbia University report (in NEJM Journal Watch ) that 15% of pregnant women were already infected with the coronavirus. Most of these had no symptoms. My supposition at the time was that these pregnant women had been in close and frequent contact with healthcare providers, prior to distancing and masking, making them more at risk of viral acquisition.
 
Now in August, there is some good news for women seeking prenatal care. Researchers in Boston have shown no difference in the average number of in-person visits between 90 pregnant women who tested positive for COVID-19 and 370 pregnant controls who did not contract the virus. The researchers say the findings “suggest in-person health care visits were not likely to be an important risk factor for infection and that necessary, in-person care can be safely performed.” Their paper is published in JAMA Network Open.
 
This findings fits as well with what we are discovering about COVID-19 transmission patterns. Unsurprisingly, household exposure to COVID-19 confers the greatest risk for transmission, while being outdoors is least risky. A recent publication in Annals of Internal Medicine studied 3400 close contacts of nearly 400 COVID-19 patients in Guangzhou, China. Overall, nearly 4% of all contacts became infected. Of these, 10% of household contacts were infected versus 1% of those exposed in healthcare settings and 0.1% of those exposed on public transportation. Interestingly, the risk for transmission increased with the severity of symptoms in the original (index) case increased. I found this to be somewhat counter intuitive given the recent emphasis on asymptomatic and presympatic spread of the virus.
 
Lastly, a study in The Lancet has calculated the risk of diabetes & COVID-19 mortality. Between March and May, the unadjusted rate of in-hospital death with COVID-19 among U.K. patients was 138 per 100,000 for those with type 1 diabetes and 260 per 100,000 with type 2 diabetes — compared with 27 per 100,000 for those without diabetes. An adjusted risk of death from COVID-19 was 2.9-fold higher for those with type 1 diabetes and 1.8-fold higher for those with type 2 diabetes.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

18 August 2020 Blog Post: COVID-19 in Los Angeles County

18 August 2020 Blog Post: COVID-19 in Los Angeles County

The general consensus among public health officials in Los Angeles County is that we are seeing improvement in COVID-19 case, hospitalization and mortality rates in Los Angeles County. I agree with their assessment and am cautiously optimistic.
 
Our analysis (presented below in Figures 1 and 2) do show a decrease in cases and deaths, although it is important to remember a 2-3 week lag time in reporting for these metrics. Nevertheless, mortality rates (Figure 1) in the County are certainly decreasing. They look to be approaching the most recent low from the week of 6/19/2020 (no doubt the 0.25 data point from the most recent week will revise upwards in the upcoming weeks due to reporting delays).
figure 1
Similarly, Figure 2 shows that case rates are also dropping – however, the last two datapoints will also revise upwards and we are more likely at a rate of around 20 cases per day per 100,000 population. This is a far cry from the steady state we had attained in June at around 9 cases per day per 100,000 population.
 
Figure two
One point of concern, however, is that testing rates are decreasing. This is a metric that should have essentially zero lag time. There has been a 24% drop off since the most recent high rate for the week ending 7/17/2020. Optimally we would like to see fewer cases in the context of more testing.
 
This brings me to my final point which is dispelling a notion of ‘turning a corner’ brought up in the attached article. This really is not an accurate description of what occurs in a pandemic among a population with little or no natural immunity. Instead we can expect a slow downtrend in cases, rather than a sharp drop.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

15 August 2020 Blog Post: Of Plagues and Children

15 August 2020 Blog Post: Of Plagues and Children

Section III of Wiliam McNeill’s classic text “Plagues and Peoples” describes the interplay between population expansion in China, the Middle East, India, Europe and the toll exacted by infectious diseases (“microparasitism” – his term). With surprisingly parallel experiences, diseases introduced into sufficiently dense population centers were highly lethal, leading to large die offs in the population. As encounters with epidemics increased (via trade and communication posts), death tolls decreased. Shortened times between successive exposures led to a larger proportion of individuals with effective immunity.
 
McNeill concludes, “an infectious disease which immunizes those who survive and which returns to a given community at intervals of five to ten years, automatically becomes a childhood disease.”
 
We are on the brink, and perhaps have already passed, COVID-19 becoming a childhood disease. Thus far, children have been relatively unaffected as the environment placing them at highest risk – schools – closed in March.
 
In California, children aged 5-17 comprise 16.7% of the population but only 7.6% of COVID-19 cases. Mortality rate in this group has been quite low: 0.002% – a case fatality rate made all the more remarkable when compared to the observed mortality rate among older adults:
 
70-74: 3.0%
75-80: 12.2%
80+: 22.9%
 
What we are seeing currently with COVID-19 is a pattern that has shaped city-states, trading routes and dynasties for millenia. A disease attacking a population without any natural resistance has resulted in sudden and large scale death.
 
Children, thus far, have been spared primarily because they have remained less often infected as compared of the rest of the population. While it remains true that COVID-19 has a far lower risk of mortality for a 14 year old as compared to an 84 year old, children have yet to bear the full brunt of the epidemic. Carelessly sending them to school without physical distancing, masks, disinfection protocols and a coherent testing plan will lead to large scale infection and, in turn, death.
 
The threat is serious enough that the CDC yesterday sent out guidance for pediatric practices. In this document, they note that although “children infected with SARS-CoV-2 are less likely to develop severe illness compared with adults, children are still at risk of developing severe illness and complications from COVID-19. Recent COVID-19 hospitalization surveillance data shows that the rate of hospitalization among children is low (8.0 per 100,000 population) compared with that in adults (164.5 per 100,000 population), but hospitalization rates in children are increasing. While children have lower rates of mechanical ventilation and death than adults, 1 in 3 children hospitalized with COVID-19 in the United States were admitted to the intensive care unit, which is the same in adults.”
 
Further, “similar to adults, children with severe COVID-19 may develop respiratory failure, myocarditis, shock, acute renal failure, coagulopathy, and multi-organ system failure. Some children with COVID-19 have developed other serious problems like intussusception or diabetic ketoacidosis. Children infected with SARS-CoV-2 are also at risk for developing multisystem inflammatory syndrome in children (MIS-C).”
 
Should you be worried? Absolutely. Florida is already experiencing COVID-19 as a childhood disease (Link: https://www.sun-sentinel.com/…/fl-ne-children-getting…). We have learned this tragic lesson across millenia and, it appears, will be learning it once again.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

10 August 2020 Blog Post: Quantifying the Effect of Case Reporting Delays – COVID-19 in Los Angeles County

10 August 2020 Blog Post: Quantifying the Effect of Case Reporting Delays - COVID-19 in Los Angeles County

When logging into the Los Angeles County Public Health COVID-19 website, the following disclaimer is presented in bright yellow highlighted text:
 
“DISCLAIMER: Public Health anticipates receiving a backlog of cases once the State electronic laboratory system issues are fixed. Data sources that track other key indicators, including hospitalizations and deaths, are not affected by this reporting issue.”
 
The Los Angeles Times has begun wringing their hands, stating that the “broken” tracking systems leaves us with “no idea” of what is going on (link below). This is a recapitulation of apparent helplessness that has gotten us into this nightmare of an epidemic. It occurred in March over lack of available testing kits, and again is on display 6 months later.
 
The difficulty with waiting for laboratory issues to be fixed (or any issue for that matter), is that we are all trying to make COVID-19 decisions in real time. So rather than waiting, I took a look at case data from Los Angeles County to quantify the duration and magnitude of this delay.
 
In order to do so, I looked at data snapshots of incident case rates at 4 different time points: 7/7, 7/14, 7/26 and 8/7. Epidemic curves for each of those dates are presented in Figure 1.
The four curves all overlap until mid to late June when they begin to diverge. At that point, it takes about a week for the curve to catch up to its actual value. There is a very large drop off in the 7/14 curve (Red Line) which, no doubt, represents delays from the July 4th weekend. The numbers presented by the County on 7/14 ultimately ended up being a 44% undercount (actually seems about right when considering a 3 day holiday- 3 days off divided by 7 days in a week = 43%).
 
Fortunately, the magnitude in undercounts due to case delays seems to have lessened since July 4th, although we are now looking at about two to three weeks to catch up. This is seen in the 7/26 data (Yellow Line) which diverges from the most recent data (Green Line) for three weeks. These undercounts are: 3.5%, 11.4% and 34.0% in each of the three successive weeks. Obviously, the further back that one goes the more likely that case data are correct and accurately tabulated.
 
Applying these correction factors to the most recent epidemic curve gives us a pretty good idea of where we are in the epidemic curve (Figure 2). Rather than having “no idea”, we actually have a pretty good idea. Instead of the steep drop off suggested by the most recent County data, we appear to be at a plateau of cases with, in fact, a slight uptick between last week and this week.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.